NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 52 resultados LastUpdate Última actualización 06/12/2016 [14:17:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   Mostrar por página


T CELL RECEPTOR-LIKE ANTIBODIES SPECIFIC FOR A PRAME PEPTIDE

NºPublicación: WO2016191246A2 01/12/2016

Solicitante:
MEMORIAL SLOAN-KETTERING CANCER CENTER [US]
EUREKA THERAPEUTICS INC [US]

Resumen de: WO2016191246A2

The presently disclosed subject matter provides antigen-binding proteins that specifically bind to Preferentially expressed antigen of melanoma (PRAME), including humanized, chimeric and fully human antibodies against PRAME, antibody fragments (e.g., scFv, Fab and F(ab)2), chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen-binding proteins and antibodies bind to a PRAME peptide/HLA class I molecule complex. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of PRAME associated diseases, including for example, breast cancer, ovarian cancer, melanoma, lung cancer, gastrointestinal cancer, brain tumor, head and neck cancer, renal cancer, myeloma, neuroblastoma, mantle cell lymphoma, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML), Non-Hodgkin lymphoma (NHL), and Chronic lymphocytic leukemia (CLL). The antibodies or antigen binding proteins may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.



traducir


 

HUMAN PRIMARY CELL CULTURE MEDIUM AND USE THEREOF

NºPublicación: WO2016187820A1 01/12/2016

Solicitante:
GUANGZHOU INST OF BIOMEDICINE AND HEALTH CHINESE ACAD OF SCIENCES [CN]

Resumen de: WO2016187820A1

Provided are a primary cell culture medium, use thereof for culturing a human primary cell in vitro, and method for utilizing the culture medium to culture a human primary B-cell acute lymphoblastic leukemia (B-ALL) cell in vitro. The primary cell culture medium comprises a base culture medium and cell factors: human FLT3L, human IGFl, human IL-7 and human IL-6, and is serum-free.



traducir


 

USE OF THE EQUIPMENT FOR STRUCTURIZATION AND POLARIZATION OF FUEL, COMBUSTION MIXTURE OR WATER AS AN EQUIPMENT FOR EXTRACORPOREAL PROCESSING OF BLOOD

NºPublicación: WO2016189336A1 01/12/2016

Solicitante:
KUREGYAN KAMO [GE]

Resumen de: WO2016189336A1

The invention relates to transfusion and to the equipment designed for processing blood for the purpose of effective treatment of various diseases, including leukemia, as well as for deactivation of viruses. Application of the known equipment (published under number WO2013050882, according to claim 1) for structurization and polarization of fuel, combustion mixture or water, as an equipment for extracorporeal treatment of blood of human or animal by the influence of electric field at the time of flowing in the channel between the electrodes made of gold and/or platinum and titanium or coated therewith, followed by reinfusion of blood into the patient's circulatory system.



traducir


 

COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF

NºPublicación: WO2016189014A1 01/12/2016

Solicitante:
MORPHOSYS AG [DE]

Resumen de: WO2016189014A1

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.



traducir


 

METHODS OF PROGNOSIS AND TREATMENT OF PATIENTS SUFFERING FROM ACUTE MYELOID LEUKEMIA

NºPublicación: WO2016189118A1 01/12/2016

Solicitante:
INSERM (INSTITUT NAT DE LA SANT\u00C9 ET DE LA RECH M\u00C9DICALE) [FR]
CENTRE HOSPITALIER REGIONAL UNIV DE LILLE [FR]
UNIVERSIT\u00C9 DE LILLE 1 SCIENCES ET TECH [FR]
UNIVERSIT\u00C9 DE DROIT ET DE LA SANT\u00C9 DE LILLE 2 [FR]

Resumen de: WO2016189118A1

The present invention relates to methods of prognosis and treatment of patients suffering from Acute Myeloid Leukemia (AML). In particular one aspect of the present invention relates to a method for predicting the survival time of a patient suffering from actue myeloid leukemia (AML) comprising determining the expression level of CD81 on leukemic cells and leukemic stem cells isolated from a sample obtained from the patient. One further object of the present invention relates to a method of treating acute myeloid leukemia in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an anti-CD81 antibody.



traducir


 

TUBULIN-BINDING COMPOUNDS, COMPOSITIONS AND USES RELATED THERETO

NºPublicación: WO2016191537A1 01/12/2016

Solicitante:
THE REGENTS OF THE UNIV OF CALIFORNIA [US]

Resumen de: WO2016191537A1

This disclosure relates to antimitotic compounds, compositions comprising therapeutically effective amounts of these compounds, and methods of using those compounds and compositions in treating hyperproliferative disorders, e.g., cancers and myelodysplastic syndromes.



traducir


 

Combinations for treating cancers

NºPublicación: AU2015290000A1 01/12/2016

Solicitante:
GILEAD SCIENCES

Resumen de: AU2015290000A1

Disclosed are combinations for treating a cancer in a subject (e.g., a human) in need thereof, comprising a therapeutically effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, and a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy. The subject who has the cancer may also be refractory to at least one chemotherapy treatment, or is in relapse after treatment with chemotherapy, or both. The cancer may be a hematologic malignancy, such as leukemia or lymphoma, or a solid tumor cancer, such as pancreatic, lung and colon cancer.



traducir


 

PRODUCTION OF NUCLEIC ACID

NºPublicación: EP3098308A1 30/11/2016

Solicitante:
THERMO FISHER SCIENT BALTICS UAB [LT]

Resumen de: EP3098308A1

The present invention provides a method for in vitro evolution of reverse transcriptase enzymes, and enzymes obtainable thereby, in particular those based on Moloney Murine Leukemia Virus reverse transcriptase.



traducir


 

B-CELL DEPLETION AS A DIAGNOSTIC MARKER

NºPublicación: WO2016184931A1 24/11/2016

Solicitante:
AMGEN RES (MUNICH) GMBH [DE]

Resumen de: WO2016184931A1

The present invention in general relates to the field of medical treatments and diagnostic markers, and more specifically to methods and uses for treatment of acute lymphocytic leukemia (ALL) which involve administration of a B-cell depleting agent. Uses and methods for conserving or increasing the number of long term survivors of ALL are also envisaged. The uses and methods provided herein comprise administration of a B-cell depleting agent and/or adjusting of the treatment regimen or dosage of the B-cell depleting agent so that the number of B-cells in the blood of the treated patients remains or falls below one B-cell/ml serum within a predefined period of time.



traducir


 

T CELL RECEPTOR WITH SPECIFICITY FOR MYELOPEROXIDASE PEPTIDE AND USES THEREOF

NºPublicación: WO2016184592A1 24/11/2016

Solicitante:
KLINIKUM RECHTS DER ISAR DER TU M\u00DCNCHEN [DE]

Resumen de: WO2016184592A1

The present invention relates to T cell receptors (TCRs) with specificity for a myeloperoxidase peptide. The present invention further relates to soluble TCR constructs, chimeric TCRs, bi-specific antibodies, nucleic acids, expression constructs and cells comprising said TCRs or TCR constructs. Moreover, the present invention relates to pharmaceutical compositions comprising such TCRs, soluble TCR constructs, chimeric TCRs, bi-specific antibodies, nucleic acids, expression constructs and/or cells. The present invention further relates to the use of such TCRs, soluble TCR constructs, chimeric TCRs, bi-specific antibodies, nucleic acids or expression constructs for generating genetically modified lymphocytes and to their use as medicaments, preferably in the detection, diagnosis, prognosis, prevention and/or treatment of a hematological neoplasia involving the expression of myeloperoxidase, preferably a leukemia involving the expression of myeloperoxidase. The present invention further relates to methods of detecting, diagnosing, prognosing, preventing and/or treating a hematological neoplasia involving the expression of myeloperoxidase, preferably a leukemia involving the expression of myeloperoxidase.



traducir


 

ANTI-GD3 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY

NºPublicación: WO2016185035A1 24/11/2016

Solicitante:
CELLECTIS [FR]

Resumen de: WO2016185035A1

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a GD3 monoclonal antibody, conferring specific immunity against GD3 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating solid tumors such as melanomas, carcinomas or liquid tumor such as T-cell lymphoblastic leukemia.



traducir


 

COMPOSITIONS AND METHODS FOR TREATMENT OF HEMATOLOGICAL MALIGNANCIES

NºPublicación: US2016340409A1 24/11/2016

Solicitante:
KAHR MEDICAL(2005) LTD [IL]
HADASIT MEDICAL RES SERVICE AND DEV CO LTD [IL]

Resumen de: US2016340409A1

Use of a chimeric protein selected from the group consisting of CTLA4-FasL and CD40-FasL proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.



traducir


 

NEW USE OF A674563 IN ACUTE LEUKEMIA CARRYING FLT3 MUTANT GENE

NºPublicación: WO2016183915A1 24/11/2016

Solicitante:
HEFEI INST OF PHYSICAL SCIENCE CHINESE ACAD OF SCIENCES [CN]
HEFEI COSOURCE PHARMACEUTICAL CO LTD [CN]

Resumen de: WO2016183915A1

Disclosed is the use of A674563 in the preparation of a medicine for treating acute myeloid leukaemia patients carrying the FLT3 mutant gene, wherein a patient with leukemia may or may not have a tolerance associated with the high expression of the FL ligand. Also disclosed is method for inhibiting acute myeloid leukemia cells carrying the FLT3 mutant gene with non-therapeutic purposes, comprising the cells being in contact with A674563.



traducir


 

METHODS AND MATERIALS FOR MONITORING MYELOMA USING QUANTITATIVE MASS SPECTROMETRY

NºPublicación: US2016341742A1 24/11/2016

Solicitante:
H LEE MOFFITT CANCER CENTER AND RES INST INC [US]

Resumen de: US2016341742A1

The subject invention concerns methods and materials for diagnosing, monitoring the progress, and/or providing a prognosis for multiple myeloma and other conditions associated with antibody production in a person or animal. The methods of the invention utilize mass spectrometry for quantitative monitoring and detection of antibody produced by the plasma cells. The methods of the invention can be utilized for diagnosis, monitoring, and/or prognosis of multiple myeloma, monoclonal gammopathy, and other immunological or hematological conditions and disorders. In addition to detecting and quantifying antibody in a sample, other biological markers, such as serum albumin and/or beta-2-microglobulin, can also be detected and quantified using the present invention, and in combination with detection and quantification of antibody. Thus, in one embodiment, both antibody and serum albumin and/or beta-2-microglobulin are detected and quantified using mass spectrometry and a diagnosis or prognosis made based on the results and levels detected.



traducir


 

EPIGENETIC STEM CELL COMMITMENT-ASSOCIATED SIGNATURE

NºPublicación: US2016340737A1 24/11/2016

Solicitante:
ALBERT EINSTEIN COLLEGE OF MEDICINE INC [US]

Resumen de: US2016340737A1

Methods for determining the prognosis of a subject having acute myeloid leukemia (AML) as well as methods of treating AML subjects depending on prognosis.



traducir


 

PROGNOSTIC MARKERS OF ACUTE MYELOID LEUKEMIA SURVIVAL

NºPublicación: WO2016183679A1 24/11/2016

Solicitante:
UNIVERSIT\u00C9 DE MONTR\u00C9AL [CA]
RSEM LTD PARTNERSHIP [CA]

Resumen de: WO2016183679A1

Methods and kits for the diagnosis and prognosis of acute myeloid leukemia (AML) are described. These methods and kits are based on the assessment of the level of expression of the gene High Mobility Group AT-hook 2 (HMGA2), and optionally of the level of expression of at least one additional prognostic marker gene such as PRKC Apoptosis WT1 Regulator (PAWR), in a biological sample from an AML patient. High levels of expression of HMGA2 and PAWR in the sample are associated with poor disease prognosis, for example low probability of survival and/or increased risk of relapse, in AML patients, including in intermediate-risk AML patients. Methods and kits for the diagnosis of AMLs with TP53 mutations based on genes differentially expressed in AMLs with TP53 mutations relative to other AMLs also described.



traducir


 

T CELL RECEPTOR WITH SPECIFICITY FOR MYELOPEROXIDASE PEPTIDE AND USES THEREOF

NºPublicación: EP3095792A1 23/11/2016

Solicitante:
KLINIKUM RECHTS DER ISAR DER TECH UNIVERSIT\u00C4T M\u00DCNCHEN [DE]

Resumen de: EP3095792A1

The present invention relates to T cell receptors (TCRs) with specificity for a myeloperoxidase peptide. The present invention further relates to soluble TCR constructs, chimeric TCRs, bi-specific antibodies, nucleic acids, expression constructs and cells comprising said TCRs or TCR constructs. Moreover, the present invention relates to pharmaceutical compositions comprising such TCRs, soluble TCR constructs, chimeric TCRs, bi-specific antibodies, nucleic acids, expression constructs and/or cells. The present invention further relates to the use of such TCRs, soluble TCR constructs, chimeric TCRs, bi-specific antibodies, nucleic acids or expression constructs for generating genetically modified lymphocytes and to their use as medicaments, preferably in the detection, diagnosis, prognosis, prevention and/or treatment of a hematological neoplasia involving the expression of myeloperoxidase, preferably a leukemia involving the expression of myeloperoxidase. The present invention further relates to methods of detecting, diagnosing, prognosing, preventing and/or treating a hematological neoplasia involving the expression of myeloperoxidase, preferably a leukemia involving the expression of myeloperoxidase.



traducir


 

METHODS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR

NºPublicación: EP3096142A2 23/11/2016

Solicitante:
CELGENE CORP [US]

Resumen de: EP3096142A2

The invention provides a method of selecting a group of cancer patients or a method of selecting a group of cancer patients responsive to treatment with thalidomide, lenalidomide, pomalidomide or 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, a stereoisomer thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, based on the level of CRBN expression, or the levels ofDDB1, DDB2, GSK3B, CUL4A, CUL4B, XBP-1, FAS1, RANBP6, DUS3L, PHGDH, AMPK, IRF4 or NFºB expression within the cancer, for the purposes of predicting clinical response, monitoring clinical response, or monitoring patient compliance to dosing by thalidomide, lenalidomide, pomalidomide or 3-(5-amino-2-methyl-4-oxo-4 H -quinazolin-3-yl)-piperidine-2,6-dione, a stereoisomer thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof; wherein the cancer patients are multiple myeloma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, melanoma; or solid tumor patients.



traducir


 

POLYCYCLIC EPOXIDES AND COMPOSITIONS THEREOF WITH ANTI-CANCER ACTIVITIES

NºPublicación: WO2016181312A1 17/11/2016

Solicitante:
VERSITECH LTD [CN]
MORNINGSIDE VENTURES LTD [CN]

Resumen de: WO2016181312A1

The present technology provides polycyclic epoxides of Formula I, compositions comprising such expoxides and methods of using such epoxides. In particular, these compounds are useful for inhibiting cancer cell proliferation and tumor angiogenesis or treating ovarian, breast, prostate, liver, pancreatic, and colon cancers, as well as leukemia.



traducir


 

NOVEL SYRINGOLIN ANALOGUES AND METHODS OF MAKING AND USING SAME

NºPublicación: WO2016182968A1 17/11/2016

Solicitante:
BROWN UNIV [US]

Resumen de: WO2016182968A1

The present invention provides, in certain aspects, novel syringolin analogues, In certain embodiments, the compounds of the invention are proteasome inhibitors, In other embodiments, the compounds treat or prevent a cancer such as, but not limited to, leukemia in a subject,



traducir


 

TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE

NºPublicación: US2016331758A1 17/11/2016

Solicitante:
VENTIRX PHARMACEUTICALS INC [US]

Resumen de: US2016331758A1

The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.



traducir


 

METHODS FOR TREATMENT OF LYMPHOMAS WITH MUTATIONS IN CELL CYCLE GENES

NºPublicación: US2016331750A1 17/11/2016

Solicitante:
MEMORIAL SLOAN KETTERING CANCER CENTER [US]

Resumen de: US2016331750A1

The present disclosure identifies a novel subtype of follicular lymphoma (FL) characterized by dysregulation of the cyclin/CDK/RB proliferative pathway. This subtype of FL is associated with increased malignancy and mortality, relative to FL which is not associated with cell cycle dysregulation. Accordingly, this disclosure presents novel methods to subtype FL and stratify patient risk by detection of biomarkers associated with RB inactivation. This disclosure further presents novel therapies for the treatment of FL subtyped by inactivation of RB.



traducir


 

COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY

NºPublicación: US2016333106A1 17/11/2016

Solicitante:
GENENTECH INC [US]

Resumen de: US2016333106A1

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.



traducir


 

HETEROCYCLIC COMPOUNDS AND THEIR USES

NºPublicación: US2016333017A1 17/11/2016

Solicitante:
AMGEN INC [US]

Resumen de: US2016333017A1

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.



traducir


 

QUANTIFICATION METHOD FOR EXPRESSION LEVEL OF WT1 mRNA

Nº publicación: US2016333415A1 17/11/2016

Solicitante:
OTSUKA PHARMA CO LTD [JP]

Resumen de: US2016333415A1

A method for quantifying the expression level of human WT1 mRNA conveniently, in a short period of time, and with high sensitivity is provided. The method can be used for diagnosing cancer, such as leukemia and solid cancer, or for determining when to perform bone marrow transplantation. The method is for quantifying the expression level of human WT1 mRNA by one-step RT-PCR and comprises simultaneously subjecting the human WT1 mRNA and a housekeeping gene (mRNA) to reverse transcription and extension reactions carried out sequentially in the same vessel.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver